Skip to main content
SleepCited

Efficacy of Lavender Essential Oil in Reducing Stress, Insomnia, and Anxiety in Pregnant Women: A Systematic Review.

Eulàlia Vidal-García, Maria Vallhonrat-Bueno, Fabià Pla-Consuegra, Alícia Orta-Ramírez
Review Healthcare (Basel, Switzerland) 2024 5 sitasi
PubMed DOI CC-BY PDF
<\/script>\n
`; }, get iframeSnippet() { const domain = 'sleepcited.com'; const params = 'pmid\u003D39685078'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

Study Design

Jenis Studi
Review
Ukuran Sampel
413
Intervensi
Efficacy of Lavender Essential Oil in Reducing Stress, Insomnia, and Anxiety in Pregnant Women: A Systematic Review. None
Pembanding
Placebo
Arah Efek
Positive
Risiko Bias
Moderate

Abstract

BACKGROUND/OBJECTIVES: During pregnancy, women can experience stress, anxiety, and insomnia, which affect their health and wellbeing. Since many conventional medications are contraindicated for pregnant women, there is a need to find alternative therapies for alleviating their discomfort. Lavender essential oil (EO) is recognized for its calming and relaxing properties; therefore, our goal was to review current knowledge of lavender EO use to reduce anxiety and stress as well as to improve sleep quality in pregnant women. METHODS: We conducted a comprehensive literature search in 11 databases that included clinical trials published between 2000 and 2022. RESULTS: Of the 251 articles found, only 6, comprising a total of 413 participants that used lavender EO during the second or third trimester of pregnancy, met the inclusion/exclusion criteria. One trial measured sleep quality, one measured anxiety, two measured both anxiety and stress, and two measured only stress. All studies reported significant (at least p < 0.05) improvement in the respective conditions and no adverse effects. CONCLUSIONS: The results obtained suggest that although the use of lavender EO during pregnancy has shown to have certain efficacy, given the small number of participants and lack of strong scientific literature, more studies are needed to provide further evidence on this topic.

Full Text

PDF
Loading PDF...

Figures

Tables

Table 1

Authors, Year. CountryStudy TypeSample Size (n)Case/ControlAge (y)Gestational Time (W)OutcomeRoute of AdministrationInterventionEvaluationResultsData Adjustment
Effati-Daryani F et al., 2018. Iran[37]RCTn:135(92/43)18 to 40 y25 to 28 wSleep qualityTopical application on their legsCase 1: 2 g cream (1.25% Lavender) every day and footbath.Case 2: 2 g cream (1.25% Lavender) every day.Control 1: 2 g placebo cream every day.PSQICase 1 vs. Control:−2.9 (−4 to 1.8) (p < 0.001)Case 2 vs. Control:−2.8 (−4 to −1.6) (p < 0.001)Adjusted for the baseline values and the stratifying factor (parity) used for random allocation
Aisyah et al., 2019. Indonesia[38]Quasi experiment50Third trimesterAnxietyInhalationGroup: Combination of lavender aromatherapy with classical musicHRS-AAfter vs. before: −17.82 (p = 0.001)Values not statistically adjusted
Effati-Daryani F et al., 2015. Iran[39]RCTn:141(94/47)18–40 y25–28 wAnxiety and stressTopical application on their legsCase 1: 2 g cream (1.25% Lavender) every day and footbath.Case 2: 2 g cream (1.25% Lavender) every day.Control 1: 2 g placebo cream every day.DASS-21Anxiety:Case 2 vs. Control (4th w):−2.33 (−3.92, −0.75)) (p = 0.002)Case 2 vs. Case 1 (8th w):−1.37 (−2.60, −0.15) (p = 0.003)Case 2 vs. Control (8th w):−1.66 (−2.87, −0.45) (p = 0.003)Stress:Case 2 vs. Case 1 (4th w):−2.30 (−4.13, −0.48) (p = 0.006)Case 2 vs. Case 1 (8th w):−3.12 (−4.70, −1.53) (p < 0.001)Case 2 vs. Control (4th w):−1.93 (−3.74, −0.12) (p = 0.006)Case 2 vs. Control (8th w):−2.70 (−4.27, −1.13) (p < 0.001)Adjusted for the baseline values and the stratifying factor (parity) used for random allocation
Igarashi T and Fujita, 2010. Japan[40]RCTn:16 (9/7)29.3 y(case)/27.3 y (control)26 wAnxiety and StressInhalationCase: Inhalation of either Lavender, Petitgrain or BergamotControl: No inhalationSTAIVASTrait anxiety (STAI):Case vs. Control(32nd and 36th w) p < 0.05Able to relax (VAS):Case vs. Control(32nd w) p < 0.05Case (32nd vs. 28th) p < 0.05Case (28th vs. 36th) p < 0.05Values not statistically adjusted
Igarashi T, 2013. Japan[41]RCTn:13 (7/6)29.3 y (case)/27.3 y (control)28 wStressInhalationCase: Inhalation of either Lavender, Petitgrain or BergamotControl: No inhalationPOMSCase vs. Control:T-A (T = −10.5, p < 0.05)A-H (T = −10.5, p < 0.05)Values not statistically adjusted
Chen P et al., 2017. Taiwan[42]RCTn:58 (28/30)20–45 y (33.31 ± 4.0)16–26 wStressTopical application via massage of head, neck, shoulders, arms, waist, back, legs, and feetCase: Oil (2% Lavender)Control: Placebo oilCortisol levels in saliva (ELISA)Case vs. Control:36 w vs. 16 w post intervention (p < 0.001)Values not statistically adjusted

References

  1. Untitled
  2. Untitled
  3. Untitled
  4. Untitled
  5. Untitled
  6. Untitled
  7. Untitled
  8. Untitled
  9. Untitled
  10. Untitled
  11. Untitled
  12. Untitled
  13. Untitled
  14. Untitled
  15. Untitled
  16. Untitled
  17. Untitled
  18. Untitled
  19. Untitled
  20. Untitled
  21. Untitled
  22. Untitled
  23. Untitled
  24. Untitled
  25. Untitled
  26. Untitled
  27. Untitled
  28. Untitled
  29. Untitled
  30. Untitled
  31. Untitled
  32. Untitled
  33. Untitled
  34. Untitled
  35. Untitled
  36. Untitled
  37. Untitled
  38. Untitled
  39. Untitled
  40. Untitled
  41. Untitled
  42. Untitled
  43. Untitled
  44. Untitled

Used In Evidence Reviews

Similar Papers